Moreover, a risk model that incorporates the gene expression-based “intrinsic” subtypes luminal A, luminal B, HER2-enriched, and basal-like was developed in order to improve standards for breast cancer prognosis and prediction of chemotherapy benefit [37,38]. The gene discussed is ERBB2; the disease is breast carcinoma.